The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.

J Hematol Oncol · 2019 · PMC6407248 · PMID 30845975

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Quantification documented highly significant reductions in cell death (Fig. 4 c).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.